Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
Phase 3
Completed
- Conditions
- SchizophreniaBipolar Disorder
- Registration Number
- NCT00113594
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents with schizophrenia or bipolar I disorder. This study will also assess the safety of olanzapine delivered orally.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Male or female patients, 13 through 17 years of age (must not have reached their 18th birthday prior to Visit 1).
- Female patients must not be pregnant or nursing.
- Patient and patient's parent/authorized legal representative must have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must have given informed consent.
- Patient must have a previously documented diagnosis of schizophrenia or bipolar I according to the DSM-IV-TR, and either confirmed previously by K-SADS-PL or be confirmed by K-SADS-PL at Visit 1.
Exclusion Criteria
- Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or bipolar I disorder.
- Patients are not allowed into the study if they currently meet the criteria for the depressed phase of bipolar disorder or are diagnosed with Bipolar II Disorder.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To characterize olanzapine pharmacokinetics The inter- and intra-subject variabilities of olanzapine pharmacokinetics The potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents 13-17 years of age that have been diagnosed with schizophrenia or bipolar I disorder
- Secondary Outcome Measures
Name Time Method To assess the safety of olanzapine delivered orally by measuring adverse events, change in vital signs, weight, laboratory analytes, electrocardiogram (ECG), and severity of extrapyramidal symptoms To assess the effect of olanzapine on overall symptomatology
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
🇷🇺Moscow, Russian Federation